Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.
Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.
Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced it will release its Q1 2025 financial results on Wednesday, May 14, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET to discuss the financial results and provide a business update. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 924151. The call will be broadcast live and archived on the company's website in the Investors section.
BioRestorative Therapies (NASDAQ:BRTX) has announced that its Vice President of Research and Development, Francisco Silva, will present an update on the company's ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease (cLDD) at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting. The presentation, titled "Phase 2 Clinical Safety/Efficacy Data of Intradiscal Injection of Hypoxic Mesenchymal Stem Cells for Lumbar Disc Disease," will take place on Thursday, May 8, from 3:45-4:45 pm CT at the conference in New Orleans, LA.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced its CEO Lance Alstodt will participate in the Benzinga All-Access Show on April 15, 2025, at 10:50 a.m. Eastern time.
During the interview, the company plans to discuss their recent achievements in clinical and regulatory milestones, along with highlighting commercial opportunities. The session will be accessible via live webcast and will subsequently be archived in the Investors section of the company's website.